CFO stock sale and new awards at Surgery Partners (SGRY)

Rhea-AI Filing Summary

Surgery Partners, Inc. Chief Financial Officer David T. Doherty reported a mix of stock sales and awards. On March 6, 2026, he sold 14,574 common shares at a weighted average price of $13.84 to cover tax withholding from recently vested restricted stock.

On March 5, 2026, he received three restricted stock awards totaling 141,743 shares at $14.11 per share. One grant vests in three equal annual installments starting one year after the grant date, while two additional grants vest on the first and second anniversaries, respectively.

After these transactions, Doherty directly held 88,803 common shares, reflecting the net effect of the tax-related sale following the vesting events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doherty David T

(Last) (First) (Middle)

C/O SURGERY PARTNERS, INC.

340 SEVEN SPRINGS WAY, SUITE 600

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Surgery Partners, Inc. [ SGRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S		14,574(1)	D	$13.84(2)	88,803	D
Common Stock	03/05/2026		A		56,697(3)	A	$14.11	145,500	D
Common Stock	03/05/2026		A		54,545(4)	A	$14.11	200,045	D
Common Stock	03/05/2026		A		30,501(5)	A	$14.11	230,546	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock on February 28, 2026 and March 2, 2026.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest in three equal annual installments beginning on the first anniversary of the Grant Date.

4. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the first anniversary of the Grant Date.

5. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the second anniversary of the Grant Date.

Remarks:

	/s/ Jennifer Baldock, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did SGRY CFO David T. Doherty report on this Form 4?

David T. Doherty reported a tax-related sale and multiple stock awards. He sold 14,574 Surgery Partners shares on March 6, 2026, and received three restricted stock awards totaling 141,743 shares on March 5, 2026, all in the company’s common stock.

How many Surgery Partners (SGRY) shares did the CFO sell, and at what price?

The CFO sold 14,574 shares of Surgery Partners common stock. The sale occurred at a weighted average price of $13.84 per share, as disclosed, with the filing noting that detailed price breakdowns for individual trades are available upon request from the company or regulators.

Why did the SGRY CFO sell 14,574 shares of common stock?

The sale was executed to satisfy tax withholding obligations. Specifically, shares were sold in connection with the vesting of restricted stock on February 28, 2026, and March 2, 2026, meaning the transaction functioned as a withholding mechanism rather than a discretionary portfolio sale.

What restricted stock awards did the Surgery Partners CFO receive on March 5, 2026?

On March 5, 2026, the CFO received three restricted stock awards totaling 141,743 shares at $14.11 per share. One award vests in three equal annual installments starting one year after grant, while the other two vest on the first and second anniversaries, respectively.

How many Surgery Partners (SGRY) shares does the CFO hold after these transactions?

Following the reported sale and grants, the CFO directly held 88,803 shares of Surgery Partners common stock. This reflected the balance after selling shares to cover tax withholding on vested restricted stock and receiving new restricted stock awards subject to time-based vesting schedules.

Are the new Surgery Partners restricted stock awards immediately vested for the CFO?

No, the awards are subject to time-based vesting. One restricted stock grant vests in three equal annual installments starting on the first anniversary of March 5, 2026, while two separate grants vest on the first and second anniversaries of that grant date, respectively.